At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 102 target
Drug / intervention
JMKX005425drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JMKX005425 Tablets in Subjects With Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating JMKX005425 for Advanced Solid Tumors. Currently recruiting, targeting 102 participants across 1 site.
Detailed Summary
This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR) advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
2026202720282029
First PostedOct 2025
Enrollment StartOct 2025
TodayJul 2026
Primary CompletionDec 2027
Study CompletionDec 2028
First PostedOct 6, 2025
Enrollment StartOct 22, 2025
Primary CompletionDec 1, 2027
Study CompletionDec 1, 2028
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 9 months agoPrimary completion in 1.4 years
Interventions
JMKX005425drug
JMKX005425 administered orally.